2026-01-19 - Analysis Report
**Company Overview:** Abbott Labs is a medical device and diagnostics global leader.

**Comparison of Return Rates:**

| Stock | Cumulative Return |
| --- | --- |
| ABT (Review Stock) | 7.92% |
| VOO (Comparison Stock) | 82.54% |

The degree of divergence on the last day of the data is: `82.54% - 7.92% = 74.62%`

**Analysis of Alpha, Beta:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 5.0% | 11.4% | 5.0% | 1.1 | 125.9B |
| 2017-2019  | 2.0% | 8.4% | -6.0% | 1.0 | 151.2B |
| 2018-2020  | 5.0% | 16.0% | -16.0% | 0.9 | 190.6B |
| 2019-2021  | 40.0% | 16.0% | 3.0% | 0.8 | 244.9B |
| 2020-2022  | -1.0% | 23.5% | -11.0% | 0.8 | 191.1B |
| 2021-2023  | -11.0% | 23.5% | -27.0% | 0.7 | 191.6B |
| 2022-2024  | -18.0% | 20.6% | -45.0% | 0.7 | 196.9B |
| 2023-2025  | -1.0% | 15.6% | -50.0% | 0.3 | 218.1B |

**Recent Stock Price Fluctuations:**

* 5-day SMA: $123.85
* 20-day SMA: $125.12
* 60-day SMA: $125.91
* Recent fluctuation: -1.43 (from 123.53 to 121.76)

**Analysis of RSI, PPO indicators and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.80 (Medium Investment)
* RSI: 39.06
* PPO: -0.24
* Recent (20 days) relative divergence change: 0.0 (flat)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.0 (flat)
* Reflecting the fluctuation issue: The recent sharp decline from 123.53 to 121.76 indicates a potential selling pressure.

**Recent News & Significant Events:**

The recent news and events suggest a recovery phase for the healthcare sector, which may benefit Abbott Laboratories. The articles highlight the company's potential to benefit from the sector's recovery and its strong dividend stock.

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.71 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 144.75 / 169.00 / 122.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-29 | $0.94 | $11.37 B$ |
| 2025-07-30 | $1.02 | $11.14 B$ |
| 2025-04-30 | $0.76 | $10.36 B$ |
| 2024-10-31 | $0.94 | $10.63 B$ |
| 2025-10-29 | $0.94 | $10.63 B$ |

The recent earnings report shows strong revenue growth, with a slight decline in EPS.

**Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

The financial information shows strong revenue growth, but a decline in profit margin and return on equity.

**Comprehensive Analysis:**

Based on the analysis, Abbott Laboratories shows a cumulative return of 7.92% compared to the S&P 500's 82.54%. The recent stock price fluctuations indicate a sharp decline, and the market risk indicator suggests a medium investment risk. The analyst opinions are predominantly positive, with a mean rating of 1.71 (Buy). The recent earnings report shows strong revenue growth, but a slight decline in EPS. The financial information indicates strong revenue growth, but a decline in profit margin and return on equity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.